Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
Clareon PanOptix Pro has half the light scatter of Clareon PanOptix 1-3,*,**
PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics 1-4,*,**,†
Clareon PanOptix Pro provides more uninterrupted light distribution across the full visual range, and is designed for better image contrast 1,††,‡
Article content
TORONTO — Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon ® PanOptix ® Pro intraocular lens (IOL) for cataract patients inCanada. PanOptix Pro leverages proprietary ENLIGHTEN ® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL. 1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics. 1-4,*,**,† These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate. 1,††,‡ PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix. 10-13,§,§§,¶,¶¶ 'Now, with PanOptix Pro, more light utilization and less light scatter is possible‡,‡‡, empowering both my practice and my patients.'
Article content
'As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D,' said Rob Scott, VP, Intraocular Devices, R&D, Alcon. 'Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro. 1,3,10.14-19,* This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world's most implanted trifocal IOL.' 1-3,20,21,*,**,‡‡,‖,Ω 'PanOptix has been a cornerstone of my cataract practice for eight years,' said Dr. Rosa Braga-Mele, MD, MEd, FRCSC, Professor of Ophthalmology, University of Toronto. 'These lenses have consistently delivered outstanding visual outcomes for my patients 10, 24, § – a low visual disturbance profile 25, ∂ and a happy patient with greater spectacle independence. 23, § So, it's exciting to see this technology evolve to further meet patients' visual expectations. Now, with PanOptix Pro, more light utilization and less light scatter is possible ‡,‡‡, empowering both my practice and my patients.'
Article content
PanOptix Pro will be available in Canada from Alcon in the single-use Clareon AutonoMe ® preloaded delivery system and as well as with the Clareon Monarch ® IV delivery system in early 2026. 22 PanOptix Pro offers a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering. 22 For surgeons interested in more information on PanOptix Pro, please speak to a local Alcon representative.
Article content
About Clareon PanOptix Pro
Article content
The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Please consult the Directions for Use regarding indications, precautions, cautions and warnings which is available at ifu.alcon.com.
Article content
About Alcon
Article content
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.ca.
Article content
* PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro 94% light utilization (6% scatter light).
** Based on manufacturer-reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner.
† For feasible diffractive optics of up to pentafocal design from Krackhardt et al.
†† Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic.
‡ Compared to Clareon PanOptix.
‡‡ Based on bench and vision simulator studies.
§Based on prospective multicenter randomized study at 6 months, significantly more subjects reported not experiencing starburst and glare (p<0.05 n=276).
§§All-implanted analysis set.
¶In response to the IOLSAT questionnaire question 'In the past 7 days, how often did you need to wear eyeglasses to see'?
¶¶Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op 'Given your vision today, if you had to do it all over, would you have the same lenses implanted again?'; n=127.
‖ Based on worldwide IOL unit sales of Clareon PanOptix and AcrySof IQ PanOptix through Q1, 2024.
Ω Severity ratings by phakic patients with simulated implant of Clareon PanOptix Pro and Clareon PanOptix using VirtIOL simulator (n=64).
∂ Based in a meta-analysis of 11 unique clinical studies with 580 patients in 10 different countries, including 'very bothersome' and 'severe' visual disturbances. Clinical studies were performed on the AcrySof IQ PanOptix IOL; AcrySof IQ PanOptix and Clareon PanOptix are optically equivalent.
Article content
References
Article content
Alcon data on file, 2025. REF-25218
Alcon data on file, 2024. REF-25221
Alcon data on file, 2015. REF-08546
Krackhardt U, et al: Upper bound on the diffraction efficiency of phase-only fanout elements. Applied Optics; 1992; 31:27-37.; 10. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston.
Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston.
Rayner Professional Website. https://rayner.com/en/iol/trifocal/rayone-trifocal/. Accessed September 2024.
Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53.
ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014.
Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; https://europe.ophthalmologytimes.com/zeiss-cataract-insight-series?page=1. Accessed September 2024.
Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234.
Alcon data on file, 2024. REF-23958.
Alcon data on file, 2018. REF-01475.
Alcon Vision LLC. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021.
Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614- 1617. doi:10.1177/154193120805201965
Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. https://www.ccohs.ca/oshanswers/ergonomics/office/.
Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164
Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal. American Journal of Ophthalmology. 2016;161. doi:10.1016/j.ajo.2015.09.030
Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/j.jcrs.0000000000000780
Alcon data on file, 2024. REF-25903
Alcon data on file, 2024. REF-23554
MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023.
Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use.
Zhu D, et al. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2):1157-1171. doi:10.1007/s40123-023-00657-5.Alcon Vision LLC.
Modi S, Lehmann R, Maxwell A, et al. Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens. Ophthalmology. 2021;128(2):197-207. doi:10.1016/j.ophtha.2020.07.015
Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Relations
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
26 minutes ago
- CTV News
How are U.S. border towns in Canada being affected amidst the trade war?
Watch The Niagara Region has seen various impacts from the on-going trade war between U.S. and Canada. CTV's Kamil Karamali has more.
Globe and Mail
4 hours ago
- Globe and Mail
3 Millionaire-Maker Technology Stocks
Key Points If quantum computing takes off in the next decade, IonQ could be a big winner. SoundHound is a company that has shown its ability to adapt, and it could become a big winner in agentic AI. Palantir has the potential to become one of the largest AI companies in the world. 10 stocks we like better than IonQ › If you're looking to invest in potential millionaire-making tech stocks, you're sometimes going to have to swing for the fences. The three stocks below are bold bets on companies chasing massive markets with long runways. You're not buying these stocks looking for modest returns; you're buying them because you see a shot at something transformational. That said, these are high-risk, high-potential-reward stocks. None of their valuations are cheap, and most are still just starting to scratch the surface of their potential. But if the technologies deliver and management teams execute, the upside could be enormous. IonQ Quantum computing company IonQ (NYSE: IONQ) isn't just an academic lab with a bunch of theoretical physics testing hypotheses, like the characters on the TV show "The Big Bang Theory." It's building real quantum computers that are already being tested in commercial, government, and academic settings. IonQ is working to build fault-tolerant systems that can operate at scale, which is the holy grail in quantum computing. Without that reliability, this emerging technology won't move beyond the lab. The company has made solid early progress. It's working with AstraZeneca, Amazon, and Nvidia on early use cases, and it has a strong balance sheet with around $700 million in cash and investments and zero debt. That gives it time and room to invest without constantly going to the market for funding. IonQ also opened a 65,000 square foot facility in Washington to manufacture systems in-house. That's another sign that this isn't just a science project anymore and that the company is gearing up to deliver working machines. The company has also been acquiring smaller quantum computing players to help bolster its capabilities. That's a smart move in a burgeoning field where technical talent and intellectual property are key. There's still a long road ahead, but if quantum computing takes off in the next decade, IonQ is positioned to be one of the companies that could be a huge winner. SoundHound AI While SoundHound AI (NASDAQ: SOUN) is still a relatively young company, it has consistently been able to adapt in an ever-evolving tech landscape. That's something great tech companies do. A leader in "speech-to-meaning" and "deep meaning understanding" technology, the company acquired Amelia last year to add its advanced conversational intelligence to its platform. It's now taking this combined technology and applying it to create voice-first artificial intelligence (AI) agents that can go out and complete tasks without the need for human intervention. By merging its voice technology with Amelia's enterprise software, SoundHound now has a complete voice automation platform. SoundHound has been strong in the automobile and restaurant industries, while Amelia brought with it expertise in the medical and financial verticals, which have their own nuances and specific industry jargon. It's also used Amelia's technology as part of the foundation for its AI agent ambitions. With the recent rollout of its Amelia 7.0 platform, it's now moved beyond being simply an AI voice company to being a voice-first agentic AI company. This is still a small company with something to prove, but the product roadmap and customer traction suggest it's heading in the right direction. And as I said at the beginning, it has been quick to adapt. The company actually started out as a platform for discovering music, where it would then direct customers to online music stores. It's come a long way since those early days, and the future looks bright. Palantir Palantir Technologies (NASDAQ: PLTR) is the largest company on this list and the one with the clearest momentum. Originally formed to help fight terrorism after 9/11, the data gathering and analytics company has been a key government vendor for years. However, it has successfully expanded into the commercial sector, where its AI platform (AIP) has become a central tool for helping organizations implement AI in the real world. Most businesses don't lack data -- they lack the tools to do anything meaningful with it. Palantir helps organizations gather data from a wide variety of sources and then structure it into an ontology that links the data to their real-world counterparts. The ontology provides clean, structured data that helps AI models operate more effectively. Customers can then apply whatever AI models they want with this ontology to identify real-world problems and then go out and solve them. AIP has been a hit with commercial customers. In Q1, its U.S. commercial revenue grew 71%, and commercial deal value more than doubled. Best of all, most of these deals are in their early stages, and Palantir has a big opportunity not just to add more customers, but to grow significantly within its existing customer base. The stock's valuation is steep, no question. However, given the breadth of use cases across industries for which AIP can be used, the company has the potential to become one of the largest AI companies in the world in the future. Should you invest $1,000 in IonQ right now? Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
CTV News
4 hours ago
- CTV News
‘Team Canada is still at the table': Trade council member Volpe on Canada-U.S. trade talks
APMA President and Canada-U.S. relations council member Flavio Volpe joins CTV to give an update on the on-going Canada-U.S. trade deal.
